Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-4/A Registration of securities issued in business combination transactions
- 5.1 Exhibit 5.1
- 8.1 Exhibit 8.1
- 10.28 Exhibit 10.28
- 10.29 Exhibit 10.29
- 10.41 Exhibit 10.41
- 10.42 Exhibit 10.42
- 10.43 Exhibit 10.43
- 10.44 Exhibit 10.44
- 10.45 Exhibit 10.45
- 10.46 Exhibit 10.46
- 10.47 Exhibit 10.47
- 10.48 Exhibit 10.48
- 10.49 Exhibit 10.49
- 10.50 Exhibit 10.50
- 10.51 Exhibit 10.51
- 10.52 Exhibit 10.52
- 10.53 Exhibit 10.53
- 10.54 Exhibit 10.54
- 10.55 Exhibit 10.55
- 10.56 Exhibit 10.56
- 10.57 Exhibit 10.57
- 10.58 Exhibit 10.58
- 10.59 Exhibit 10.59
- 10.60 Exhibit 10.60
- 10.61 Exhibit 10.61
- 10.62 Exhibit 10.62
- 10.63 Exhibit 10.63
- 10.64 Exhibit 10.64
- 10.65 Exhibit 10.65
- 10.66 Exhibit 10.66
- 10.67 Exhibit 10.67
- 10.68 Exhibit 10.68
- 10.69 Exhibit 10.69
- 10.70 Exhibit 10.70
- 10.71 Exhibit 10.71
- 23.1 Exhibit 23.1
- 23.2 Exhibit 23.2
- 99.1 Exhibit 99.1
- EX-FILING FEES Filing Fees Table
- Download Excel data file
- View Excel data file
Associated filings
- 5 Dec 22 424B3 Prospectus supplement
- 14 Nov 22 EFFECT Notice of effectiveness
- 10 Nov 22 424B3 Prospectus supplement
- 4 Nov 22 S-4/A Registration of securities issued in business combination transactions (amended)
- 24 Oct 22 S-4/A Registration of securities issued in business combination transactions (amended)
-
3 Oct 22 S-4/A Registration of securities issued in business combination transactions (amended)
- 29 Aug 22 S-4 Registration of securities issued in business combination transactions
KA similar filings
Filing view
External links
Exhibit 23.2
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM’S CONSENT
We consent to the inclusion in this Registration Statement on Amendment No. 1 to Form S-4 (File No. 333-267127) of Yumanity Therapeutics, Inc. of our report dated August 26, 2022 with respect to our audits of the consolidated financial statements of Kineta, Inc. (“Kineta”) as of December 31, 2021 and 2020 and for the years ended December 31, 2021 and 2020, which includes an explanatory paragraph as to Kineta’s ability to continue as a going concern, which report appears in the proxy statement/prospectus/information statement, which is part of this Registration Statement. We also consent to the reference to our Firm under the heading “Experts” in such proxy statement/prospectus/information statement.
/s/ Marcum llp
Marcum llp
New York, NY
October 3, 2022